Aubagio (teriflunomide) is a small molecule pharmaceutical. Teriflunomide was first approved as Aubagio on 2012-09-12. It is used to treat relapsing-remitting multiple sclerosis in the USA. It has been approved in Europe to treat multiple sclerosis. The pharmaceutical is active against dihydroorotate dehydrogenase (quinone), mitochondrial. Aubagio's patents are valid until 2034-02-04 (FDA).
|Indication||multiple sclerosis, relapsing-remitting multiple sclerosis|